Clinical and magnetic resonance imaging features of idiopathic oculomotor neuropathy in 14 dogs: Canine Idiopathic Oculomotor Neuropathy

Ophthalmoplegia/ophthalmoparesis (internal, external, or both) has been reported in dogs secondary to neoplasia affecting the oculomotor nerve and is usually given a poor prognosis. The purpose of this retrospective study was to describe the clinical findings, magnetic resonance imaging (MRI) findings, management, outcome, and follow-up in a group of canine cases with idiopathic oculomotor neuropathy. Inclusion criteria included cases with ophthalmoplegia/ophthalmoparesis (internal, external or both) as sole neuroophthalmologic signs, complete ophthalmic and neurologic examination, head MRI, and a minimum follow-up period of 1 year. Dogs with progressive neurological signs not related to oculomotor neuropathy were excluded. Fourteen cases met the inclusion criteria. All cases were unilaterally affected. Magnetic resonance imaging showed equivocal enlargement of the oculomotor nerve in three cases, mild enlargement in five, and marked enlargement in six. Contrast enhancement was present in 12 cases, being marked in six. When present, the contrast enhancement was focal in eight cases and diffuse in four. The median follow-up time was 25 months. External ophthalmoparesis improved in seven cases, five cases under no treatment and two under systemic corticosteroid therapy. The clinical signs in the other seven cases remained unchanged. Idiopathic oculomotor neuropathy should be included as a differential diagnosis in dogs presenting with unilateral ophthalmoplegia/ophthalmoparesis (internal, external, or both) with the absence of other neurologic and ophthalmic signs, and with the MRI findings restricted to the oculomotor nerve. Idiopathic oculomotor neuropathy has a good prognosis as the clinical signs do not deteriorate and they can improve without treatment

Clinical signs, imaging findings, and outcome in twelve cats with internal ophthalmoparesis/ophthalmoplegia

Objective To retrospectively evaluate the clinical signs, imaging ?ndings, and outcomeof feline internal opht halmoparesis/ophthalmoplegia.Procedure Medical records were reviewed from 2008 to 2015. Inclusion criteriaincluded cats that presented with internal ophthalmoparesis/o phthalmoplegia, under-went diagnostic imaging, and had follow-up information available.Results Twelvecases of felineinternal ophthalmoparesis/ophthalmoplegia wereidenti?ed.Nine cats were unilaterally affected, and three cats were bilaterally affected. Affectedcats had a median age of 10.54 years (range 5.75 to 13.17), and both sexes of var yingbreeds were affected (nine males; three females). Clinical signs including abnormalmental status (n = 9; 75%) and additional neurologic abnor malities ( n = 10; 83%)were observed. Magnetic resonance imaging and/or compute d tomography (MRI/CT)of the head were performed in ten cats, revealing a mass lesion in all cases with vary-ing locations. Multicentric lymphoma was diagnosed in two cats via abdominal ultra-sound and cytology. All twelve cats were euthanized due to deterioration of clinicalsigns and/or quality-of-life concern s. Median time from diagnosis to euthana sia was3.5 days (range 0 to 80 days).Conclusions Feline internal ophthalmoparesis/ophthalmoplegia rarely presents as thesole clinical sign in a referral hospital. Advanced imaging (MRI/CT) may be necessaryto reach a de?nitive diagnosis in these cases. However, abdominal ultr asound wouldbe advocated in cats with systemic clinical signs as a less expensive and less invasivediagnostic test to further investigate the possible etiology of internal ophthalmopare-sis/ophthalmoplegia prior to advanced imaging. Feline cases with internal ophthalmo-paresis/ophthalmoplegia associated with other intracranial signs and/or systemicclinical signs have a poor prognosis

Los bajos tipos de interés. El mayor desafío para el sector asegurador europeo

Màster de Direcció d'Entitats Asseguradores i Financeres, Universitat de Barcelona, Facultat d'Economia i Empresa, Curs: 2019-2020, Tutor: Enric Fernández MartínezEsta tesis explora el entorno financiero al que se deberá enfrentar el sector asegurador europeo, caracterizado por unos tipos de interés de referencia muy bajos o negativos, y la respuesta que las entidades deberán dar al mismo. Ante la posibilidad de que éste entorno se alargue en el tiempo, las entidades aseguradoras deberán hacer un gran esfuerzo y gestionar su balance contable acorde a ello. La imposibilidad de obtener retornos financieros libres de riesgo positivos conllevará la necesidad de diseñar nuevos productos que puedan ofrecer retornos atractivos en este contexto tan complejo

Assaying activity and assessing thermostability of hyperthermophilic enzymes

There is now a wide variety of intra- and extra-cellular enzymes available from organisms growing above 75°C, and having sufficient stability to allow assay well above this temperature. For some of these enzymes, to assay below even 95°C will involve measurement below the optimal growth temperature for the organism. The purpose of this chapter is to cover practical aspects of enzyme assay procedures that are specific to high temperatures. Since by far the commonest routine assessment of enzyme stability is activity loss, and because it is always unwise to measure enzyme activity without being confident of its stability during the assay, we include an outline of procedures for measuring enzyme activity loss/stability at high temperatures

Breed and conformational predispositions for prolapsed nictitating membrane gland (PNMG) in dogs in the UK : A VetCompass study

Background Prolapsed nictitating membrane gland (PNMG) is the most common disorder of the third eyelid in dogs. However, the epidemiology of PNMG in the wider dog population remains understudied. Methods Using de-identified clinical data from the VetCompass Programme, this cohort study aimed to report the prevalence, demographic and breed-related risk factors of PNMG in dogs attending UK primary care veterinary practices in 2016. Results There were 1,802 PNMG cases identified from 905,543 dogs, yielding an annual prevalence of 0.20% (95% confidence interval (CI) 0.19–0.21). The median age at first diagnosis was 0.63 years (IQR 0.33–1.98, range 0.11–18.00). Dogs aged under 1 year had 10.82 times the odds (95% CI 9.17–12.76) compared with dogs aged from 2 to under 4 years. Neutered animals had higher odds than entire animals within both sexes. Breeds with the highest odds of PNMG compared with crossbred dogs included Neapolitan Mastiff (odds ratio (OR) 34.26, 95%CI 15.92–73.75), English Bulldog (OR 24.08, 95% CI 20.62–28.13), Cane Corso (OR 14.66, 95% CI 8.18–26.28), Lhasa Apso (OR 12.37, 95% CI 10.26–14.92) and American Cocker Spaniel (OR 11.57, 95% CI 5.59–23.96). Purebred dogs had 1.43 times the odds (95% CI 1.26–1.63) of PNMG compared with crossbreed dogs. Breeds with brachycephalic skull conformation had 6.71 times the odds (95%CI 5.89–7.64) compared with breeds with mesocephalic skull conformation. Insured dogs had 1.89 times the odds (95% CI 1.65–2.16) compared with uninsured dogs. Conclusions This study reports the largest cohort of primary-care PNMG cases assembled to date. The results showing young age at diagnosis along with the breed, purebred and brachycephalic skull conformation predispositions suggest a hereditary involvement in PNMG development. These results may help to guide breeding strategies to reduce the prevalence of PNMG and improve welfare in predisposed individuals.Background Prolapsed nictitating membrane gland (PNMG) is the most common disorder of the third eyelid in dogs. However, the epidemiology of PNMG in the wider dog population remains understudied. Methods Using de-identified clinical data from the VetCompass Programme, this cohort study aimed to report the prevalence, demographic and breed-related risk factors of PNMG in dogs attending UK primary care veterinary practices in 2016. Results There were 1,802 PNMG cases identified from 905,543 dogs, yielding an annual prevalence of 0.20% (95% confidence interval (CI) 0.19–0.21). The median age at first diagnosis was 0.63 years (IQR 0.33–1.98, range 0.11–18.00). Dogs aged under 1 year had 10.82 times the odds (95% CI 9.17–12.76) compared with dogs aged from 2 to under 4 years. Neutered animals had higher odds than entire animals within both sexes. Breeds with the highest odds of PNMG compared with crossbred dogs included Neapolitan Mastiff (odds ratio (OR) 34.26, 95%CI 15.92–73.75), English Bulldog (OR 24.08, 95% CI 20.62–28.13), Cane Corso (OR 14.66, 95% CI 8.18–26.28), Lhasa Apso (OR 12.37, 95% CI 10.26–14.92) and American Cocker Spaniel (OR 11.57, 95% CI 5.59–23.96). Purebred dogs had 1.43 times the odds (95% CI 1.26–1.63) of PNMG compared with crossbreed dogs. Breeds with brachycephalic skull conformation had 6.71 times the odds (95%CI 5.89–7.64) compared with breeds with mesocephalic skull conformation. Insured dogs had 1.89 times the odds (95% CI 1.65–2.16) compared with uninsured dogs. Conclusions This study reports the largest cohort of primary-care PNMG cases assembled to date. The results showing young age at diagnosis along with the breed, purebred and brachycephalic skull conformation predispositions suggest a hereditary involvement in PNMG development. These results may help to guide breeding strategies to reduce the prevalence of PNMG and improve welfare in predisposed individuals.Peer reviewe

Presumed optic neuritis of non‐infectious origin in dogs treated with immunosuppressive medication: 28 dogs (2000‐2015)

Objective To describe the clinical findings, magnetic resonance imaging features, management and outcome of canine cases with presumed optic neuritis of non‐infectious origin that were presented to a UK referral centre from January 2000 to December 2015. Materials and Methods The clinical database was searched for optic neuritis. Dogs with acute‐onset vision impairment, systemic immunosuppressive treatment and follow‐up of ≥6 months were included. Information collected included: age; gender; breed; clinical signs and duration; physical, ophthalmic and neurological examination findings; concurrent systemic disease; and results of electroretinogram, magnetic resonance imaging, cerebrospinal fluid analysis, polymerase chain reaction and serology testing for Toxoplasma gondii, Neospora caninum and canine distemper virus, haematology and serum biochemistry profiles, abdominal ultrasound, thoracic radiography, treatment and outcome. Results Twenty‐eight dogs were included, with a total of 48 affected optic nerves. Age at presentation ranged from 6 months to 10.5 years. Fundoscopic evidence of optic nerve disease was present in 34 of 48 (71%) optic nerves. Magnetic resonance imaging revealed enlargement of 32 of 48 (67%) nerves and contrast enhancement of 28 of 48 (58%) nerves. Cerebrospinal fluid analysis performed in 25 of 28 (89%) dogs revealed pleocytosis (>5 nucleated cells/uL) in 11 of 25 (44%) and increased protein (>0.35 g/L) in 11 of 25 (44%). Immunosuppressive prednisolone was administered to all dogs. Prednisolone was used alone in 9 of 28 (32%) dogs; the remaining 19 dogs received a combination of prednisolone with cytosine arabinoside, cyclosporine and/or azathioprine. Vision was recovered in 24 eyes (50%) of 18 affected dogs. Clinical Significance A positive response to treatment was observed in 64% of dogs with presumptively diagnosed optic neuritis treated with immunosuppressive medication

Clinical, histopathological and genetic characterisation of oculoskeletal dysplasia in the Northern Inuit dog

Seven Northern Inuit Dogs (NID) were diagnosed by pedigree analysis with an autosomal recessive inherited oculoskeletal dysplasia (OSD). Short-limbed dwarfism, angular limb deformities and a variable combination of macroglobus, cataracts, lens coloboma, microphakia and vitreopathy were present in all seven dogs, while retinal detachment was diagnosed in five dogs. Autosomal recessive OSD caused by COL9A3 and COL9A2 mutations have previously been identified in the Labrador Retriever (dwarfism with retinal dysplasia 1-drd1) and Samoyed dog (dwarfism with retinal dysplasia 2-drd2) respectively; both of those mutations were excluded in all affected NID. Nine candidate genes were screened in whole genome sequence data; only one variant was identified that was homozygous in two affected NID but absent in controls. This variant was a nonsense single nucleotide polymorphism in COL9A3 predicted to result in a premature termination codon and a truncated protein product. This variant was genotyped in a total of 1,232 dogs. All seven affected NID were homozygous for the variant allele (T/T), while 31/116 OSD-unaffected NID were heterozygous for the variant (C/T) and 85/116 were homozygous for the wildtype allele (C/C); indicating a significant association with OSD (p = 1.41x10-11). A subset of 56 NID unrelated at the parent level were analysed to determine an allele frequency of 0.08, estimating carrier and affected rates to be 15% and 0.6% respectively in NID. All 1,109 non-NID were C/C, suggesting the variant is rare or absent in other breeds. Expression of retinal mRNA was similar between an OSD-affected NID and OSD-unaffected non-NID. In conclusion, a nonsense variant in COL9A3 is strongly associated with OSD in NID, and appears to be widespread in this breed